OAM
RPRX icon

Oppenheimer Asset Management’s Royalty Pharma RPRX Stock Holding History

Oppenheimer Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-27,932
Closed -$1.11M – 1244
2021
Q4 		$1.11M Buy
+27,932
New +$1.09M 0.01% 747

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Oppenheimer Asset Management's RPRX Position: Q1 2022 in Review

Oppenheimer Asset Management sold out of Royalty Pharma (RPRX) in Q1 2022, closing a stake of 27,932 shares — an estimated $1.11M sold.

Oppenheimer Asset Management first reported a position in RPRX in Q4 2021 and held it in 1 quarter. The position peaked at $1.11M in Q4 2021. 279 funds tracked by Wall St. Rank hold RPRX as of Q1 2022.

  • Oppenheimer Asset Management reported no remaining Royalty Pharma position as of Q1 2022 after selling out during the quarter.
  • Oppenheimer Asset Management sold 27,932 Royalty Pharma shares in Q1 2022, an estimated $1.11M.
  • Oppenheimer Asset Management first reported a position in Royalty Pharma in Q4 2021 and held it in 1 quarter.
  • Oppenheimer Asset Management's Royalty Pharma position peaked at $1.11M in Q4 2021.
  • 279 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2022.

Based on Oppenheimer Asset Management's 13F filing for Q1 2022, filed 12 May 2022.